Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction

References

• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet200536521722315652604
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSBanegasJRHypertension prevalence and blood pressure levels in 6 European countries, Canada and the United StatesJAMA20032892363236912746359
   PubMed Web of Science ®Google Scholar
• KearneyPMWheltonMReynoldsKWheltonPKHeJWorldwide prevalence of hypertension: a systematic reviewJ Hypertens200422111915106785
   PubMed Web of Science ®Google Scholar
• Marques-VidalPArveilerDAmouyelPBinghamAFerrièresJSex differences in awareness and control of hypertension in FranceJ Hypertens199715120512109383168
   PubMed Web of Science ®Google Scholar
• BurtVLWheltonPRoccellaEJPrevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988–1991Hypertension1995253053137875754
   PubMed Web of Science ®Google Scholar
• De HenauwSDe BacquerDFonteyneWStamMKornitzerMDe BackerGTrends in the prevalence, detection, treatment and control of arterial hypertension in the Belgian adult populationJ Hypertens1998162772849557920
   PubMed Web of Science ®Google Scholar
• PsaltopoulouTOrfanosPNaskaALenasDTrichopoulosDTrichopoulouAPrevalence, awareness, treatment and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC studyInt J Epidemiol2004331345135215218014
   PubMed Web of Science ®Google Scholar
• AsmarRVolSPannierBBrisacAMTichetJEl HasnaouiAHigh blood pressure and associated cardiovascular risk factors in FranceJ Hypertens2001191727173211593091
   PubMed Web of Science ®Google Scholar
• Guidelines CommitteeEuropean Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens2003211011105312777938
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRProspective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studiesLancet20023601903191312493255
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens2007251105118717563527
   PubMed Web of Science ®Google Scholar
• HymanDJPavlikVNCharacteristics of patients with uncontrolled hyper tension in the United StatesN Engl J Med200134547948611519501
   PubMed Web of Science ®Google Scholar
• MorimotoSOgiharaTTCV-116: a new angiotensin II type-1 receptor antagonistCardiovasc Drug Rev199412153164
   Web of Science ®Google Scholar
• HübnerRHögemannAMSunzelMRiddellJGPharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteersJ Hum Hypertens199711Suppl 2S19S25
   PubMed Web of Science ®Google Scholar
• OjimaMInadaYShiboutaYCandesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptorEur J Pharmacol19973191371469030909
   PubMed Web of Science ®Google Scholar
• NodaMShiboutaYInadaYInhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonistBiochem Pharmacol1993463113188347154
   PubMed Web of Science ®Google Scholar
• ElmfeldtDGeorgeMHubnerROlofssonBCandesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effectJ Hum Hypertens199711Suppl 2S49S539331007
   PubMed Web of Science ®Google Scholar
• ReifMWhiteWBFaganTCfor the Candesartan Cilexetil Study InvestigatorsEffects of candesartan cilexetil in patients with systemic hypertensionAm J Cardiol1998829619659794352
   PubMed Web of Science ®Google Scholar
• FabiaMJAbdillaNOltraRFernandezCRedonJAntihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoringJ Hypertens2007251327133617563549
   PubMed Web of Science ®Google Scholar
• JuliusSNesbittSDEganBMfor the Trial of Preventing Hypertension (TROPHY) Study InvestigatorsFeasibility of treating prehypertension with an angiotensin-receptor blockerN Engl J Med20063541685169716537662
   PubMed Web of Science ®Google Scholar
• SkovKEiskjærHHansenHEMadsenJKKvistSMulvanyMJTreatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blockerHypertension200750899517485597
   PubMed Web of Science ®Google Scholar
• HasebeaNKikuchiaKfor the NICE Combi Study GroupControlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE COMBI (Nifedipine and Candesartan Combination) StudyJ Hypertens20052344545315662234
   PubMed Web of Science ®Google Scholar
• BonnerGCalderBDzyakGAntihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapyBlood Press200817Suppl 2S22S30
   Web of Science ®Google Scholar
• SasakiHKanaiSOyamaTMiyashitaYYamamuraSShiraiKEffect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitusJ Atheroscler Thromb20061314915716835470
   PubMed Web of Science ®Google Scholar
• KarlsonBWZetterstrandSOlofssonBElmfeldtDA dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertensionBlood Press20091814915619462314
   PubMed Web of Science ®Google Scholar
• AnderssonOKNeldamSThe antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartanBlood Press1998753599551878
   PubMedGoogle Scholar
• KlonerRAWeinbergerMPoolJLfor the Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study InvestigatorsComparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertensionAm J Cardiol20018772773111249891
   PubMed Web of Science ®Google Scholar
• MogensenCENeldamSTikkanenIfor the CALM Study GroupRandomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) StudyBMJ20003211440144411110735
   PubMed Web of Science ®Google Scholar
• AndersenNHPoulsenPLKnudsenSTLong-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. The CALM II studyDiabetes Care20052827327715677778
   PubMed Web of Science ®Google Scholar
• The ONTARGET InvestigatorsTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520
   PubMed Web of Science ®Google Scholar
• ChaturvediNPortaMKleinRfor the DIRECT Programme Study GroupEffect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsLancet20083721394140218823656
   PubMed Web of Science ®Google Scholar
• SjølieAKKleinRPortaMfor the DIRECT Programme Study GroupEffect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialLancet20083721385139318823658
   PubMed Web of Science ®Google Scholar
• ChaturvediNSjolieAKStephensonJMEffect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitusLancet199835128319433426
   PubMed Web of Science ®Google Scholar
• BaguetJPAsmarRValensiPNisse-DurgeatSMallionJMEffects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients; the MITEC studyVasc Heslth Risk Martag20095175183
   PubMedGoogle Scholar
• PfefferMASwedbergKGrangerCBfor the CHARM Investigators and CommitteesEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet200336275976613678868
   PubMed Web of Science ®Google Scholar
• McMurrayJJVÖstergrenJSwedbergKfor the CHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM-Added trialLancet200336276777113678869
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKfor the CHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet200336277778113678871
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJVYusufSfor the CHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet200336277277613678870
   PubMed Web of Science ®Google Scholar
• McKelvieRSYusufSPericakDComparison of candesartan, enalapril, and their combination in congestive heart failure Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study InvestigatorsCirculation19991001056106410477530
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIfor the SCOPE Study GroupThe Study on COgnition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trialJ Hypertens20032187588612714861
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAfor the ACCESS Study GroupThe ACCESS study evaluation of acute candesartan cilexetil therapy in stroke survivorsStroke2003341699170312817109
   PubMed Web of Science ®Google Scholar
• OgiharaTNakaoKFukuiTfor the Candesartan Antihypertensive Survival Evaluation in Japan Trial GroupEffects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan TrialHypertension20085139339818172059
   PubMed Web of Science ®Google Scholar
• KasanukiHHagiwaraNHosodaSfor the HIJ-CREATE InvestigatorsAngiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)Eur Heart J2009301203121219346521
   PubMed Web of Science ®Google Scholar
• WakeyamaTOgawaHIidaHEffects of candesartan and probucol on restenosis after coronary stenting results of insight of stent intimal hyperplasia inhibition by new angiotensin ii receptor antagonist (ISHIN) trialCirc J20036751952412808270
   PubMed Web of Science ®Google Scholar
• LindholmLHPerssonMAlaupovicPCarlbergBSvenssonASamuelssonOMetabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)J Hypertens2003211563157412872052
   PubMed Web of Science ®Google Scholar
• ErikssonJWJanssonPCarlbergBHydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation. The Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) StudyHypertension2008521030103718981327
   PubMed Web of Science ®Google Scholar
• KohKKQuonMJLeeYAdditive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patientsEur Heart J2007281440144717483542
   PubMed Web of Science ®Google Scholar
• AsmarRNisse-DurgeatSA large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE studyVasc Health Risk Manag20062331732317326337
   PubMedGoogle Scholar